BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gondim MVP, Sherrill-Mix S, Bibollet-Ruche F, Russell RM, Trimboli S, Smith AG, Li Y, Liu W, Avitto AN, DeVoto JC, Connell J, Fenton-May AE, Pellegrino P, Williams I, Papasavvas E, Lorenzi JCC, Salantes DB, Mampe F, Monroy MA, Cohen YZ, Heath S, Saag MS, Montaner LJ, Collman RG, Siliciano JM, Siliciano RF, Plenderleith LJ, Sharp PM, Caskey M, Nussenzweig MC, Shaw GM, Borrow P, Bar KJ, Hahn BH. Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption. Sci Transl Med 2021;13:eabd8179. [PMID: 33441429 DOI: 10.1126/scitranslmed.abd8179] [Cited by in Crossref: 2] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Adams P, Berkhout B, Pasternak AO. Towards a molecular profile of antiretroviral therapy-free HIV remission. Curr Opin HIV AIDS 2022;17:301-7. [PMID: 35938464 DOI: 10.1097/COH.0000000000000749] [Reference Citation Analysis]
2 Guo K, Barrett BS, Morrison JH, Mickens KL, Vladar EK, Hasenkrug KJ, Poeschla EM, Santiago ML. Interferon resistance of emerging SARS-CoV-2 variants. Proc Natl Acad Sci U S A 2022;119:e2203760119. [PMID: 35867811 DOI: 10.1073/pnas.2203760119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Lichterfeld M, Gao C, Yu XG. An ordeal that does not heal: understanding barriers to a cure for HIV-1 infection. Trends Immunol 2022;43:608-16. [PMID: 35905706 DOI: 10.1016/j.it.2022.06.002] [Reference Citation Analysis]
4 Vieira VA, Herbert N, Cromhout G, Adland E, Goulder P. Role of Early Life Cytotoxic T Lymphocyte and Natural Killer Cell Immunity in Paediatric HIV Cure/Remission in the Anti-Retroviral Therapy Era. Front Immunol 2022;13:886562. [PMID: 35634290 DOI: 10.3389/fimmu.2022.886562] [Reference Citation Analysis]
5 Ta TM, Malik S, Anderson EM, Jones AD, Perchik J, Freylikh M, Sardo L, Klase ZA, Izumi T. Insights Into Persistent HIV-1 Infection and Functional Cure: Novel Capabilities and Strategies. Front Microbiol 2022;13:862270. [PMID: 35572626 DOI: 10.3389/fmicb.2022.862270] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Giron LB, Abdel-Mohsen M. Viral and Host Biomarkers of HIV Remission Post Treatment Interruption. Curr HIV/AIDS Rep 2022. [PMID: 35438384 DOI: 10.1007/s11904-022-00607-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kreider EF, Bar KJ. HIV-1 Reservoir Persistence and Decay: Implications for Cure Strategies. Curr HIV/AIDS Rep 2022. [PMID: 35404007 DOI: 10.1007/s11904-022-00604-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
8 Zaongo SD, Ouyang J, Chen Y, Jiao Y, Wu H, Chen Y. HIV Infection Predisposes to Increased Chances of HBV Infection: Current Understanding of the Mechanisms Favoring HBV Infection at Each Clinical Stage of HIV Infection. Front Immunol 2022;13:853346. [DOI: 10.3389/fimmu.2022.853346] [Reference Citation Analysis]
9 Winans S, Yu HJ, de Los Santos K, Wang GZ, KewalRamani VN, Goff SP. A point mutation in HIV-1 integrase redirects proviral integration into centromeric repeats. Nat Commun 2022;13:1474. [PMID: 35304442 DOI: 10.1038/s41467-022-29097-8] [Reference Citation Analysis]
10 Zacharopoulou P, Marchi E, Ogbe A, Robinson N, Brown H, Jones M, Parolini L, Pace M, Grayson N, Kaleebu P, Rees H, Fidler S, Goulder P, Klenerman P, Frater J. Expression of type I interferon-associated genes at antiretroviral therapy interruption predicts HIV virological rebound. Sci Rep 2022;12:462. [PMID: 35013427 DOI: 10.1038/s41598-021-04212-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Blazkova J, Gao F, Marichannegowda MH, Justement JS, Shi V, Whitehead EJ, Schneck RF, Huiting ED, Gittens K, Cottrell M, Benko E, Kovacs C, Lack J, Sneller MC, Moir S, Fauci AS, Chun TW. Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy. Nat Med 2021;27:1893-8. [PMID: 34711975 DOI: 10.1038/s41591-021-01503-6] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
12 Vignoles M, Andrade V, Noguera M, Brander C, Mavian C, Salemi M, Paredes R, Sharkey M, Stevenson M. Persistent HIV-1 transcription in CD4+ T cells from ART-suppressed individuals can originate from biologically competent proviruses. J Virus Erad 2021;7:100053. [PMID: 34621530 DOI: 10.1016/j.jve.2021.100053] [Reference Citation Analysis]
13 Yeh YJ, Yang K, Razmi A, Ho YC. The Clonal Expansion Dynamics of the HIV-1 Reservoir: Mechanisms of Integration Site-Dependent Proliferation and HIV-1 Persistence. Viruses 2021;13:1858. [PMID: 34578439 DOI: 10.3390/v13091858] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Tauzin A, Espinosa Ortiz A, Blake O, Soundaramourty C, Joly-Beauparlant C, Nicolas A, Droit A, Dutrieux J, Estaquier J, Mammano F. Differential Inhibition of HIV Replication by the 12 Interferon Alpha Subtypes. J Virol 2021;95:e0231120. [PMID: 33980591 DOI: 10.1128/JVI.02311-20] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Thorne LG, Bouhaddou M, Reuschl AK, Zuliani-Alvarez L, Polacco B, Pelin A, Batra J, Whelan MVX, Ummadi M, Rojc A, Turner J, Obernier K, Braberg H, Soucheray M, Richards A, Chen KH, Harjai B, Memon D, Hosmillo M, Hiatt J, Jahun A, Goodfellow IG, Fabius JM, Shokat K, Jura N, Verba K, Noursadeghi M, Beltrao P, Swaney DL, Garcia-Sastre A, Jolly C, Towers GJ, Krogan NJ. Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variant. bioRxiv 2021:2021. [PMID: 34127972 DOI: 10.1101/2021.06.06.446826] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 22.0] [Reference Citation Analysis]